Market Closed -
Nasdaq
04:00:00 2024-05-28 pm EDT
|
5-day change
|
1st Jan Change
|
1.92
USD
|
-0.52%
|
|
-4.00%
|
-18.30%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
365.4
|
180.9
|
324.6
|
286.1
|
-
|
-
|
Enterprise Value (EV)
1 |
365.4
|
180.9
|
324.6
|
286.1
|
286.1
|
286.1
|
P/E ratio
|
-1.89
x
|
-1.9
x
|
-5.22
x
|
-4.57
x
|
-9.19
x
|
40.2
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
7.37
x
|
1.64
x
|
1.98
x
|
1.55
x
|
1.3
x
|
1.1
x
|
EV / Revenue
|
7.37
x
|
1.64
x
|
1.98
x
|
1.55
x
|
1.3
x
|
1.1
x
|
EV / EBITDA
|
-
|
-2.59
x
|
-10.5
x
|
-39.5
x
|
21.2
x
|
7.89
x
|
EV / FCF
|
-3,781,797
x
|
-1,748,878
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
124,709
|
135,985
|
138,125
|
148,256
|
-
|
-
|
Reference price
2 |
2.930
|
1.330
|
2.350
|
1.930
|
1.930
|
1.930
|
Announcement Date
|
3/10/22
|
3/8/23
|
3/6/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
2.722
|
20.44
|
49.59
|
110.2
|
163.9
|
184.6
|
219.4
|
260.5
|
EBITDA
1 |
-121.3
|
-82.08
|
-
|
-69.7
|
-30.85
|
-7.249
|
13.52
|
36.25
|
EBIT
1 |
-122.4
|
-83.55
|
-115.2
|
-81.94
|
-44.01
|
-35.68
|
-4.06
|
32.09
|
Operating Margin
|
-4,495.96%
|
-408.84%
|
-232.22%
|
-74.32%
|
-26.85%
|
-19.33%
|
-1.85%
|
12.32%
|
Earnings before Tax (EBT)
1 |
-126
|
-91.25
|
-122.7
|
-96.08
|
-63.5
|
-56.45
|
-24.75
|
12.43
|
Net income
1 |
-125.6
|
-91.14
|
-122.7
|
-94.66
|
-62.26
|
-60.6
|
-30.94
|
8.422
|
Net margin
|
-4,613.52%
|
-446%
|
-247.48%
|
-85.86%
|
-37.98%
|
-32.84%
|
-14.1%
|
3.23%
|
EPS
2 |
-
|
-
|
-1.550
|
-0.7000
|
-0.4500
|
-0.4220
|
-0.2100
|
0.0480
|
Free Cash Flow
|
-105.5
|
-80.94
|
-96.62
|
-103.4
|
-
|
-
|
-
|
-
|
FCF margin
|
-3,874.1%
|
-396.06%
|
-194.84%
|
-93.8%
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/11/20
|
3/9/21
|
3/10/22
|
3/8/23
|
3/6/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
21.43
|
22.07
|
25.31
|
29.72
|
33.14
|
33.2
|
38.01
|
48.32
|
44.39
|
40.64
|
44.83
|
48.32
|
51.22
|
52.15
|
54.5
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-12.09
|
-
|
-
|
-
|
-
|
-
|
-3.463
|
-0.103
|
2.759
|
-
|
-
|
EBIT
1 |
-48.27
|
-29.07
|
-18.92
|
-18.78
|
-15.17
|
-13.28
|
-15.98
|
-4.913
|
-9.841
|
-14.24
|
-9.882
|
-6.597
|
-4.936
|
-4.55
|
-2.7
|
Operating Margin
|
-225.26%
|
-131.72%
|
-74.75%
|
-63.18%
|
-45.77%
|
-40%
|
-42.04%
|
-10.17%
|
-22.17%
|
-35.05%
|
-22.04%
|
-13.65%
|
-9.64%
|
-8.72%
|
-4.95%
|
Earnings before Tax (EBT)
1 |
-50.79
|
-34.12
|
-26.52
|
-22.17
|
-13.27
|
-16.83
|
-20.52
|
-12.53
|
-13.63
|
-18.67
|
-15.29
|
-12.07
|
-10.43
|
-9.5
|
-7.65
|
Net income
1 |
-50.79
|
-33.71
|
-26.18
|
-21.83
|
-12.93
|
-16.83
|
-19.84
|
-12.19
|
-13.39
|
-18.98
|
-16.37
|
-13.98
|
-11.28
|
-9.5
|
-7.65
|
Net margin
|
-237.02%
|
-152.74%
|
-103.47%
|
-73.44%
|
-39.01%
|
-50.71%
|
-52.2%
|
-25.23%
|
-30.16%
|
-46.71%
|
-36.52%
|
-28.92%
|
-22.02%
|
-18.22%
|
-14.04%
|
EPS
2 |
-0.4400
|
-0.2500
|
-0.1900
|
-0.1600
|
-0.1000
|
-0.1200
|
-0.1400
|
-0.0900
|
-0.1000
|
-0.1400
|
-0.1083
|
-0.0900
|
-0.0733
|
-0.0650
|
-0.0550
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/10/22
|
5/11/22
|
8/10/22
|
11/9/22
|
3/8/23
|
5/9/23
|
8/8/23
|
11/9/23
|
3/6/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-105
|
-80.9
|
-96.6
|
-103
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
1.11
|
0.38
|
1.09
|
0.52
|
2.26
|
2.25
|
2.75
|
4
|
Capex / Sales
|
40.67%
|
1.84%
|
2.19%
|
0.48%
|
1.38%
|
1.22%
|
1.25%
|
1.54%
|
Announcement Date
|
3/11/20
|
3/9/21
|
3/10/22
|
3/8/23
|
3/6/24
|
-
|
-
|
-
|
Last Close Price
1.93
USD Average target price
4.9
USD Spread / Average Target +153.89% Consensus |
1st Jan change
|
Capi.
|
---|
| -18.30% | 286M | | +38.59% | 727B | | -7.89% | 354B | | +15.66% | 328B | | +0.24% | 277B | | +13.47% | 243B | | +7.35% | 205B | | -6.42% | 203B | | +4.23% | 164B | | -1.70% | 164B |
Other Pharmaceuticals
|